glp-1 adoption New Demand in an Old Market The Evolution of GLP-1 Users

Both doses produced large weight-loss effects, but dropout from gastrointestinal adverse events was higher at 12 mg than at 9 mg

Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid these medications due to the potential risk of thyroid C-cell tumors

however, clinical trials assessing the efficacy of oral semaglutide (Rybelsus) in obesity are still enrolling participants (NCT05442450)

it is not approved by the MHRA or EMA and has no licensed dosing regimen for routine UK clinical use

Excess weight can often lead to digestive issues, including acid reflux (also called GERD or heartburn)